UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS

Their core work

University Medical Center Göttingen (UMG) is a major German academic medical center combining clinical care with deep neuroscience and biomedical research. Their core strength lies in advanced microscopy and imaging techniques applied to understanding neural circuits, synaptic function, and sensory systems — from cochlear optogenetics to super-resolution brain imaging. They also contribute significantly to clinical research in areas like rare diseases, cancer monitoring, and neurodegenerative conditions. UMG bridges fundamental neuroscience discovery with translational medical applications, particularly in diagnostics and imaging tool development.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), UMG's portfolio was broad and exploratory — spanning cardiac clinical trials (BETA3_LVH), rehabilitation robotics (WALKEr), prosthetics (INPUT), health tourism (CHARMED), and foundational neuroscience (OptoHear, CODE4Vision). From 2019 onward, a clear consolidation emerged around two pillars: advanced imaging/microscopy technologies (ULTRARESOLUTION, IMAGEOMICS, MitoCRISTAE) and applied diagnostics including cancer monitoring (CAST, PRISAR2) and rare disease screening (SCREEN4CARE). The shift reflects a maturing strategy where fundamental neuroscience imaging expertise is being channeled into diagnostic and clinical applications.

UMG is consolidating around ultra-resolution imaging as a platform technology, increasingly applying it to clinical diagnostics, rare diseases, and neurodegenerative conditions — making them a strong partner for projects needing imaging-based biomarker discovery.

How they like to work

UMG operates as both a project leader and an active consortium member, coordinating 13 of 30 projects (43%) — a high coordination rate for a university medical center. Their coordinated projects tend to be ERC grants and smaller focused research actions, while they join larger multi-partner clinical and translational consortia (like AIMS-2-TRIALS, ESCAPE, SCREEN4CARE) as specialist contributors. With 226 unique partners across 24 countries, they maintain a wide but non-exclusive network, suggesting they are open to new collaborations and bring specific methodological expertise rather than relying on repeat partnerships.

UMG has collaborated with 226 unique partners across 24 countries, indicating a broad European network without strong geographic concentration. Their partnerships span from large clinical trial consortia to focused bilateral ERC-level collaborations.

What sets them apart

UMG combines world-class microscopy and imaging infrastructure (STED, STORM, expansion microscopy, nanoprobes) with deep neuroscience domain knowledge — a combination few European medical centers can match at this level. Their high ERC success rate (8 ERC grants out of 30 projects) signals individually excellent principal investigators rather than just institutional mass. For consortium builders, UMG offers the rare ability to contribute both the imaging technology platform and the biological expertise to interpret what the images reveal, particularly in neural and synaptic contexts.

Highlights from their portfolio

• ULTRARESOLUTION
  Their largest grant (EUR 3.08M ERC Advanced), pushing imaging beyond conventional super-resolution limits to study synapse physiology — represents the pinnacle of their imaging expertise.
• OptoHear
  EUR 2.5M ERC Starting Grant in cochlear optogenetics — a distinctive niche combining optics with auditory prosthetics that few groups worldwide pursue.
• SCREEN4CARE
  Large-scale rare disease project (EUR 931K to UMG) combining newborn genetic screening with machine-learning phenotyping — shows their pivot toward digital diagnostics and translational impact.